NORCROSS, Ga., March 11 /PRNewswire-FirstCall/ -- Immucor, Inc., a global leader in providing automated instrument-reagent systems to the blood transfusion industry, announced today that it has signed a definitive agreement to acquire BioArray Solutions Ltd., a privately held company based in Warren, NJ that has pioneered the development of molecular diagnostic systems which enable rapid and comprehensive antigen determination for donors and recipients of blood transfusions by DNA analysis (genotyping) using its proprietary BeadChip(TM) system for molecular medicine.
BioArray's BeadChip(TM) system deploys planar arrays of proprietary encoded microparticles to perform rapid and reliable molecular analysis of nucleic acids and proteins. Its recently launched transfusion genotyping system is currently installed in a number of leading donor and transfusion centers for research use only. Immucor will acquire in this transaction the broad intellectual property portfolio BioArray has generated through its substantial investments in research and development, including approximately 100 issued or pending patents. Immucor plans for BioArray to continue to be based in Warren, NJ and operate under the BioArray Solutions name.
Gioacchino De Chirico, President & CEO of Immucor, said, "This is a landmark acquisition for Immucor which will enable us to provide innovative molecular diagnostic solutions for blood transfusions that complement our current product line. Our leadership in blood banking industry automation and BioArray's leadership in molecular diagnostic systems for specialty transfusion applications should allow the combined company to develop and deliver more precise genotyping solutions to enhance patient outcomes. This acquisition also opens up broader opportunities for Immucor in transplantation and transfusion-related applications."
Michael Seul, CEO of BioArray, said, "We are delighted to join the
Immucor team and welcome this opportuni
|SOURCE Immucor, Inc.|
Copyright©2008 PR Newswire.
All rights reserved